Last reviewed · How we verify
NCT03854994
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
Phase 1 trial testing Anti-CD19 CAR-T Cells Injection in B Cell Lymphoma in 10 participants. Status unknown.
1 August 2021
Quick facts
| Lead sponsor | Yan'an Affiliated Hospital of Kunming Medical University |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 1 August 2018 |
| Primary completion | 1 August 2021 |
| Estimated completion | 1 August 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Anti-CD19 CAR-T Cells Injection — full drug profile →
Conditions studied
- B Cell Lymphoma — all drugs for B Cell Lymphoma →
- B-cell Acute Lymphoblastic Leukemia — all drugs for B-cell Acute Lymphoblastic Leukemia →
Sponsor
Yan'an Affiliated Hospital of Kunming Medical University
Who can join
18 and older, any sex, with B Cell Lymphoma or B-cell Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to evaluate the safety and clinical activity of anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T)infusion in the treatment of relapsed/refractory B-cell Lymphoma and B-cell acute lymphoblastic leukemia （B-ALL）.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advances in chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Yin Z, Zhang Y, Wang X. · · 2021 · cited 30× · PMID 34256851 · DOI 10.1186/s40364-021-00309-5
Verify or expand the search:
- PubMed search for NCT03854994
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anti-CD19 CAR-T Cells Injection
Trials testing the same drug.
- NCT04289220 — Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphobl · Phase 1 · unknown
Other recruiting trials for B Cell Lymphoma
Currently open trials in the same condition.
- NCT07009002 — BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma · Phase 1, PHASE2 · recruiting
- NCT06976437 — A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors · EARLY_PHASE1 · recruiting
- NCT06987916 — Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
- NCT07101913 — Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma. · active not recruiting
- NCT06742996 — A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib · Phase 3 · recruiting
Other Yan'an Affiliated Hospital of Kunming Medical University trials
Trials by the same sponsor.
- NCT07469371 — CLEAR-AS: CT-FFR-Guided Revascularization in Patients With Severe Aortic Stenosis · NA · recruiting
- NCT07485816 — A Study on the Correlation Between Cardiac-Cerebral Oxygenation Reserve and Cognitive Function Changes in Heart Failure · enrolling by invitation
- NCT06892730 — Safety and Efficacy of TEVAR Combined With Long Bare-metal Stents in the Intervention of ATBAD · NA · not yet recruiting
- NCT05611190 — CT-FFR-guided Strategy for In-stent Restenosis · NA · unknown
- NCT04125329 — Umbilical Cord Mesenchymal Stem Cells Therapy for Diabetic Nephropathy · EARLY_PHASE1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03854994 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yan'an Affiliated Hospital of Kunming Medical University
- Last refreshed: 26 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03854994.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing